Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03913130 · ClinicalTrials.gov registry record · Phase 1
Extension Study to Study PQ-110-001 (NCT03140969)
A Phase 1 study, sponsored by Laboratoires Thea.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03913130: Clinical Trial Phase 1 study, sponsored by Laboratoires Thea.
NCT03913130 is a Phase 1 study that was terminated before completion, run by Laboratoires Thea. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03913130, a Phase 1 study, was terminated before completion, sponsored by Laboratoires Thea.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.
Primary Outcome
Frequency of ocular adverse events (AEs)
Interventions
- DRUG QR-110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-05-13 |
| Est. Completion | 2022-10-03 |
| Phase | Phase 1 |
Why NCT03913130 stopped before completion
NCT03913130 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which QR-110 is the first listed.
NCT03913130 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03913130 about?
NCT03913130 is a clinical study titled "Extension Study to Study PQ-110-001 (NCT03140969)". Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety,...
What is the current status of trial NCT03913130?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-05-13. Estimated completion is 2022-10-03.
What interventions are being tested in trial NCT03913130?
The interventions under investigation include: QR-110 (DRUG).
Who is sponsoring clinical trial NCT03913130?
This trial is sponsored by Laboratoires Thea, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03913130's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI